Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...
Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...
Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...
Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...
By Dana PiccoliNEWS IS OUT The Choose U World AIDS Day panel brought together three longtime advocates living with HIV to ...
Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google. It is the first work ...
Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue ...
Over time, clonal expansion leads to an increase in the frequency of infected cells in a patient. The proviruses in daughter ...
An updated Canadian guideline on HIV prevention addresses the expanding range of medications available to reduce the risk of ...
A group often forgotten about in the discussion of HIV – despite research pointing to an ongoing crisis – is Black women in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback